

























































Controlling the Uptake of Diarylethene-Based
Cell-Penetrating Peptides into Cells Using Light
Tim Schober,[a] Ilona Wehl,[b] Sergii Afonin,[c] Oleg Babii,[c] Anna Iampolska,[d, e] Ute Schepers,[b]
Igor V. Komarov,*[d, f] and Anne S. Ulrich*[a, c]
We report on diarylethene (DAE)-containing photoswitchable
cell-penetrating peptides (CPPs) capable of photocontrolled cell
entry. We demonstrate in vitro that reversible photoisomeriza-
tion of a DAE fragment in the backbones of non-cytotoxic cyclic
peptides influences their binding to cell membranes and
subsequent CPP-mediated cargo internalization. Benign red
light can be used to activate cell entry of our compounds. We
suggest that the observed differences in cell uptake of the two
photoisomers are due to changes in the molecular flexibility
achieved upon DAE photoisomerization.
Membrane proteins that are exposed on the cell surface
currently constitute the major drug targets,[1a] but many more
“druggable” biomolecules are located inside a cell.[1b–d] Delivery
of drug molecules to their specific intracellular targets could
enhance therapeutic efficacy and reduce toxicity of the drugs.
Accordingly, the discovery of cell-penetrating peptides (CPPs)
has attracted great interest in pharmacology and medicinal
chemistry, because CPPs promise to serve as universal vehicles
to facilitate intracellular delivery of biologically active cargoes.[2]
Numerous structurally unrelated sequences have been demon-
strated to be effective as CPPs, ranging from hydrophobic
through amphipathic to highly polar cationic peptides.[2c] CPPs
were shown to be efficient as covalent conjugates or within
non-covalent assemblies with a variety of biologically active
macromolecular cargoes[2a] and nanoparticles.[2d,e] CPPs and the
ambiguities associated with their in vivo applications have
been extensively reviewed.[3]
Even 30 years after the first CPP (HIV-TAT) had been
described,[4a] no CPP-drug combination has been clinically
approved.[4b] Unfavorable pharmacokinetic characteristics of
CPPs are the main reasons, as they generally possess low
bioavailability due to their high polarity and susceptibility to
in vivo proteolysis. Meanwhile, several design principles have
been suggested to alleviate these challenges, namely: (i)
peptide backbone N-methylation,[5] (ii) macrocyclisation,[6] in-
cluding side-chain “stapling”,[7] (iv) use of robust scaffolds like
“knottins”,[8] and/or (v) equipping the peptides with “chame-
leonic” properties, i. e. dynamically exposing/shielding the
uptake-promoting chemical moieties within flexible
conjugates.[9]
However, there is another major disadvantage which many
CPPs intrinsically have when applied in vivo: they tend to be
poorly cell-type selective. CPPs may effectively transport drugs
into cells, but their unfavorable biodistribution can lead to
delivery into the wrong organs and tissues, i. e. not to the
desired sites of action. This may lead to an enhancement of
unwanted side effects and systemic toxicity.[4,10]
The selectivity problem is common to many peptide-based
macromolecular therapeutics. It can be tackled (i) by conjuga-
tion to targeting molecules, for example, to antibodies[11a] (ii) by
engrafting the sequence elements possessing enhanced cell-
type, organ, and/or tissue-affinity,[11b] or (iii) by developing
peptides that can be selectively activated by external or
internal stimuli at the desired site of action.[12] The latter
approach has been successfully applied to CPPs. For instance,
charged amines or guanidinium groups in cationic CPPs have
been temporarily blocked via carboxylic groups of glutamate or
aspartate residues in a “charge-zipper”-like manner. The charge
neutralization makes the polar CPPs cell-impermeable. Two
oppositely charged peptidyl fragments in these constructs are
connected through a linker that selectively degrades at a
specific site in vivo, e.g., by a reducing microenvironment, by
acidic hydrolysis, or by specific proteolysis in tumors.[13] The
polycationic CPP sequence released upon cleavage of the linker
becomes cell-permeable, hence it can deliver a covalently
conjugated cargo inside the surrounding cells.
The release of bioactive molecules triggered by various
external stimuli has been extensively explored. Recently, the
[a] T. Schober, Prof. Dr. A. S. Ulrich
Karlsruhe Institute of Technology (KIT),
Institute of Organic Chemistry (IOC)
Fritz-Haber-Weg 6, 76131 Karlsruhe (Germany)
E-mail: anne.ulrich@kit.edu
[b] Dr. I. Wehl, Prof. Dr. U. Schepers
KIT, Institute of Functional Interfaces (IFG)
POB 3640, 76021 Karlsruhe (Germany)
[c] Dr. S. Afonin, Dr. O. Babii, Prof. Dr. A. S. Ulrich
KIT, Institute of Biological Interfaces (IBG-2)
POB 3640, 76021 Karlsruhe (Germany)
[d] A. Iampolska, Prof. Dr. I. V. Komarov
Taras Shevchenko National University of Kyiv,
Vul. Volodymyrska 60,01601 Kyiv (Ukraine)
[e] A. Iampolska
Enamine Ltd., Vul. Chervonotkatska 78, 02094 Kyiv (Ukraine)
[f] Prof. Dr. I. V. Komarov
Lumobiotics GmbH
Auerstraße 2, 76227 Karlsruhe (Germany)
E-mail: igor.komarov@lumobiotics.com
Supporting information for this article is available on the WWW under
https://doi.org/10.1002/cptc.201900019
An invited contribution to a Special Issue on Photoresponsive Molecular
Switches and Machines
© 2019 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA.
This is an open access article under the terms of the Creative Commons
Attribution Non-Commercial License, which permits use, distribution and
reproduction in any medium, provided the original work is properly cited
and is not used for commercial purposes.
CommunicationsDOI: 10.1002/cptc.201900019
384ChemPhotoChem 2019, 3, 384–391 © 2019 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA
Wiley VCH Mittwoch, 05.06.2019


























































use of non-ionizing light for this purpose has gained particular
attention, because of high spatial and temporal precision of
light irradiation and its orthogonality to most biological
processes.[14] Light-activatable CPPs have been developed by
several groups. For example, the concept of “photocaging”[15]
has been applied to CPPs[16] by masking their polycationic
moieties with photolabile protecting groups that deactivate
cell-permeability. Subsequent irradiation with light irreversibly
unmasks the charges and triggers cell entry. However, “uncag-
ing” is problematic in vivo, because it often requires irradiation
with short-wavelengths (usually UV) light. The UV light is toxic
and has very low tissue penetration efficiency. For applications
of light in vivo, however, the use of wavelengths within the
non-toxic, tissue-penetrating optical window (red-near infrared
light, wavelength 625–900 nm) is required.[14]
Photopharmacology is a recently introduced approach to
control the biological activity of compounds by the action of
light, using photochromic molecules that can be reversibly
isomerized.[17] These molecules, called molecular photoswitches,
undergo changes in color, geometry, flexibility, polarity or
charge upon photoinduced isomerization.[18]
There are only a few papers describing photoswitchable
CPPs. Prestel and Möller used an azobenzene fragment as a
photoswitchable linker between two linear polypeptide strands
to photocontrol the cellular uptake.[19] The azobenzene linker in
the cis-configuration brought an oligoglutamate strand in close
proximity to an oligoarginine sequence, promoting the for-
mation of an intramolecular Arg-Glu-“charge-zipper” that
prevents the cellular uptake. Irradiation with visible light
converted the linker into the trans-isomer, pulling the “charge-
zipper” apart and thereby triggering membrane translocation.
Azobenzene-derived fragments have also been used as side
chain “staples” for helical peptides, enabling photocontrol of
their secondary structure and cell-entry.[20] Nevola et al. de-
scribed azobenzene-“stapled” inhibitors of a protein-protein
interaction and demonstrated photoregulation of clathrin-
mediated endocytosis.[21] Recently, Kim et al. reported a cell-
penetrating amphiphilic peptide that was “stapled” with an
azobenzene moiety.[22] A cell-permeable α-helix could only be
formed when the azobenzene fragment was in the cis-
configuration, so the UV-induced switch from trans- to cis-
configuration promoted cell permeabilization of the peptide.
This is in contrast to a construct described by Prestel and
Möller,[19] where the cis-isomer was less cell-permeable.
To the best of our knowledge, none of the described
photocontrollable CPPs could be light-activated by wave-
lengths within the tissue-penetrating optical window, despite
considerable progress has been made in the design of red-
shifted photoswitches, for example, modified azobenzenes.[14c,d]
Aiming at practical in vivo applications of photoswitchable
CPPs, we were particularly interested in using red light to
promote cellular uptake. Previously, we had explored di-
arylethene (DAE) moieties in the backbones of cyclic peptides
to photocontrol their cytotoxic activity.[23] We have developed a
DAE-based building block which mimics a β-turn element
within a cyclic β-hairpin scaffold (Scheme 1). The DAE-modified
β-hairpin peptides can exist in two thermally stable photoforms
(open and closed, Scheme 1). The open photoforms have been
successfully generated by red light (wavelength in the range
617–660 nm) even in living tissues.[23b]
Scheme 2 illustrates the general design concept which we
used to construct the molecules for this study. The basic idea
was to confine two short linear polypeptide strands between
two turns, one being the DAE fragment, and the other one –
the β-turn motif D-Xxx-L-Pro (D-Xxx being an α-D-amino acid
residue, e.g. D-Tyr). As a cargo, we selected a fluorescein-
derived fragment (to be exploited as a fluorescence reporter of
the cell uptake), which was attached via a covalent linker to the
tyrosyl oxygen in the β-turn. It is well-known that fluorescein as
a CPP cargo might impede the cell-permeability,[23] but we
attached it to the peptide via a sufficiently long and stable
linker to at least avoid the steric influence on the peptide
fragment.
Due to their small ring size, the macrocycles of our
constructs are relatively rigid. Hence the amino acid side chains
should prefer a certain spatial geometry. This side chain
arrangement and peptide dynamics can be modified upon
photoisomerization of the DAE fragment.[24] We hypothesized
Scheme 1. The photoswitchable diarylethene (DAE)-derived amino acid
building block used in this work: In comparison with a β-turn fragment.
Scheme 2. i) Structural template of the photoswitchable cyclic peptides
explored in this study and ii) general concept of their use as red-light-
triggered CPPs. The total number of amino acids in the cell-penetrating
moiety and the side chains are varied (see Table 2). All peptides contain a
fluorescein-derived moiety (as a cargo/fluorophore) connected through an
aminohexylated tyrosine side chain (linker) to track the cell uptake. All
backbone-cyclized peptides are designed to form β-hairpin structures. The
photoswitch-containing fragment (colored) mimics a β-turn unit.
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that such perturbation might directly influence the membrane-
permeability of the molecules. Importantly, in order to use red
light for switching the CPP activity on, the ability of the
molecules to enter cells should be higher when the DAE
fragment is converted from the closed to the open photoform.
The cargo delivery would thus be triggered by light within the
tissue-permeating optical window.
When choosing the amino acids to be grafted onto our
macrocyclic template, we took advantage of the results
published in the literature on efficient cyclic CPPs. Pei et al.
developed cyclic peptides which are not only proteolytically
stable and exceptionally effective as CPPs, but which can also
escape endosomes and therefore can deliver cargoes all the
way into the cytosol.[25,26] Macrocyclic constructs with a tetra-
arginyl fragment followed by 2–3 consecutive aromatic
residues were found to outperform the known “classical” linear
CPPs, such as nonaarginine (R9), HIV-TAT, or penetratin.
[26] We
also took into account the known fact that aromatic residues
can form strong π-π-interactions in β-hairpins when placed
onto apposing strands.[27,28] Similarly, hydroxyl-bearing residues
are known to form interstrand side chain-to-backbone hydro-
gen bonds in short β-hairpin-structured peptides.[29] We
reasoned that the π-π-interactions and additional hydrogen
bonds could stabilize the β-stranded structure in the open
photoforms, thus enhancing the efficiency of the photoswitch-
ing. Based on these literature data, we designed a series of
amphipathic peptides 1–5 (Table 1).
It has been also reported that proteolytically stable and
comparatively rigid cyclic oligoarginines are better CPPs than
their flexible linear analogues.[30] In line with this observation,
another study had demonstrated that rigidly pre-oriented side
chains bearing guanidinium groups can enhance the uptake[31]
of an oligoarginine-like polycationic CPP, provided that the
distances between positive charges within the peptidomimetic
matched the spacing of negative charges on membrane-
exposed polyanionic glycosaminoglycans.[32] We used these
data in the design of our second series of peptides 6–8
(Table 1).
For all experiments, the peptides 1–8 bearing the DAE
moiety in the closed form were prepared and purified (for
details see Supporting Information, SI). They were quantita-
tively converted into the corresponding open photoforms with
visible light immediately before the experiments. Absorption
properties and kinetics of full conversion of the closed photo-
forms to the corresponding open ones were studied by UV-Vis
spectroscopy and HPLC in separate experiments. We found that
virtually complete conversion (closed to open) can be induced
by irradiation with red light (617–660 nm). Figure 1 illustrates
that the photoconversion rates triggered by yellow (LED λmax=
590 nm), amber (LED λmax=617 nm) and deep-red (LED λmax=
660 nm) light (irradiance ~25 mW/cm2) are high and practically
similar; in most experiments described below we used yellow
light due to technical reasons. Perfect isosbestic points
observed in the UV-Vis spectra (see the SI) during the photo-
conversion indicated that the process was two-component, and
that the peptides were stable during photoisomerization. No
side products were detected by HPLC analysis after photo-
switching.
First, we assessed the overall hydrophobicity of the
peptides by measuring their chromatographic retention times
(RTs) on a reversed-phase C18-column with a uniform gradient
(water/acetonitrile) elution. To a first approximation, RTs reflect
the general hydrophobicities of the cationic molecules at low/
neutral pH, and could thus be used to rank our compounds
according to their predicted membrane-binding affinities.[33]
The RT values for peptides 1–8 measured under the conditions
described in the literature[34b] are listed in Table 2. As expected,
the amphipathic peptides 1–5 were significantly more hydro-
phobic (they have longer RTs) than the arginine-rich derivatives
6–8.
Among the amphipathic peptides 1–3 (closed), the less
hydrophobic ones were those where the naphthylalanine
residue was replaced by Trp or Phe. Peptide 4 (closed)
appeared significantly less hydrophobic than the other amphi-
Table 1. Sequences of the studied peptides. Analogues 1–5 were designed
to be amphipathic. Peptides 6–8 are oligoarginines and are therefore
cationic.
Peptide Sequence[a] Cycle size[b] Net charge
amphipathic series







5 cyclo[ΦFRRyAhxPRR] 9-mer +4
oligoarginine series





[a]Φ: the DAE fragment, yAhx: O-aminohexylated D-tyrosine, Nal: 2-
naphthylalanine, [b] assuming Φ to be equivalent of two amino acid
residues
Figure 1. Time-dependent DAE-closed to DAE-open photoconversion of
peptide 5 under irradiation with commercial LEDs. Yellow trace: using an
LED with λmax=590 nm, orange: with λmax=617 nm, and red: with
λmax=660 nm. Absorbance at 575 nm is present only in the closed DAE and
is therefore used to track the amount of the closed photoform. A 50 μM
solution of pure closed 5 in 50 MeOH  H2O (50 :50 v/v) was exposed to LED
illumination under continuous stirring. All the graphs correspond to
irradiance of ~25 mW/cm2
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pathic analogues, which can be explained by the presence of
the polar Thr residue. Among the oligoarginine series 6–8, the
more charged peptides were increasingly more polar. The open
photoforms with the flexible DAE fragment that might promote
structuring consistently revealed longer RTs (and, correspond-
ingly, higher hydrophobicities) when compared to their closed
isomers. This correlation gave us the confidence that photo-
switching the DAE moieties in our constructs should indeed
change the membrane affinities of the peptides, because
hydrophobicity is the most obvious property of peptides that
directly determines their strength of the initial interaction with
eukaryotic cell membranes.
We noticed some interesting trends in the hydrophobicity
profiles upon photoswitching when analyzing the differences
between RT (open) and RT (closed) (ΔRTs, Table 2). Peptide 1
(open) is the most hydrophobic in both photoforms, with the
largest ΔRT. Peptide 3 with two apposing Phe residues became
more hydrophobic upon switching to the open form than
peptide 2 with a corresponding Phe/Trp pair. Interestingly,
compound 4 bearing Thr demonstrated the third largest ΔRT,
indicating that the Thr side chain might indeed be capable of
forming intramolecular hydrogen bond in the flexible (open)
photoform, as we had suggested. For the arginine-rich
derivatives 6–8, we observed only limited changes in the RT
upon photoswitching. Obviously, the subtle changes in the
structure and dynamics of the oligo-Arg backbone upon
photoswitching are not sufficient to modulate overall hydro-
phobicity of 6–8.
As a next step, we studied the cytotoxicity of the peptides
1–8. The closed and open forms were examined separately
(Figure 2). As controls in the cytotoxicity and uptake studies
four FITC labelled peptides were taken: a linear oligoarginine
derivative (9), a cyclic oligoarginine derivative (10), a cyclic
non-photoswitchable (DAE-free) analogue of 4 (11), and non-
photoswitchable linear analogue of 4 (12) (the structures are
shown in SI). We used the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl-tetrazolium bromide) assay with HeLa cells to check
the cell viability after 72 h of incubation with 1–8 over a
concentration range of 1–20 μM, where “classical” CPPs are
effective and arginine-rich CPPs were reported to be relatively
non-toxic.[34a] In general, the closed forms showed slightly lower
cytotoxicity than the corresponding open forms. Only peptide
8 (both open and closed) with the largest number of arginine
residues caused the cell viability to decrease to below 50% at
20 μM. This result correlates with previous observations that
increasing the number of arginine residues enhances the
cytotoxicity of (R)n CPPs.
[34] Lower concentrations of 8, as well
as of other peptides, showed no significant toxicity at all tested
concentrations for both photoforms. We observed no simple
correlation between cytotoxicity and hydrophobicity. The most
hydrophobic peptide 1 (open) did not show the highest
cytotoxicity, whereas the most polar 8 (closed) seems to have
the strongest effect on eukaryotic cell viability.
Finally, the uptake of the peptides into eukaryotic cells was
examined. We used confocal fluorescence microscopy to assess
whether our peptides are cell-penetrating, and if so, whether
there are any differences in the uptake efficiency between the
open and closed forms. Pure closed forms of the peptides were
used as starting stock solutions and were switched to the open
forms with visible light (λ=590 nm) before adding them to the
cells. We used the same concentration range 1–20 μM as in the
toxicity experiments, but the incubation time was less (3 h
instead of 72 h) to ensure less cytotoxicity. After co-incubation
with peptides, trypan blue (TB)[35] was added to the extracellular
medium to quench the fluorescence of the non-internalized
peptides. A representative set of experimental data is shown in
Figure 3. As can be seen, all our peptides showed detectable
uptake within the tested concentration range. Figure 4 shows
magnified images of the cells treated with representatives of
the two series [4 (open), and 8 (open)]. No nuclear delivery is
evident, as there is no apparent co-staining with the nuclear
dye.
For the oligoarginine derivatives 7–8 and peptide 2 we
could not detect any significant difference in uptake between
the closed and open forms. However, we were pleased to see
that for peptide 6 and the amphipathic peptides 1, 3–5 an
increased uptake of the open forms was observed. This finding
justifies the design and suggests that compounds 1–5 could be
a good starting point for the development of drug delivery
systems in vivo, because the open forms, as pointed out earlier,
can be generated by benign red light. The control linear
Table 2. Retention times (RTs) of the pure closed and open photoforms of
the CPPs 1–8 on a reversed-phase C18 HPLC column (see the SI for details).
Peptide RT (closed) [min] RT (open) [min] ΔRT [min]
1 34.3 40.8 6.5
2 32.1 37.4 5.3
3 32.4 37.9 5.5
4 27.7 33.4 5.7
5 32.2 34.2 2.0
6 24.8 25.5 0.7
7 22.9 23.6 0.7
8 22.1 22.6 0.5
Figure 2. Cytotoxicity of the photoswitchable CPPs 1–8 and controls 9–12
assessed through an MTT assay with HeLa cells. The concentration range
comprises earlier reported effective concentrations of peptides with
comparable composition. Metabolic cell viability was calculated relating to
the negative control (no peptide was added to the growth media).
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oligoarginine peptide 9 showed relatively low uptake while the
cyclic oligoarginine 10 demonstrated much better CPP activity
at a level similar to the photoswitchable oligoarginine 8. On
the other hand, controls 11 and 12 (cyclic and linear non-
photoswitchable analogues of 4, correspondingly) did not
show any observable uptake, most probably because they do
not have an amphipathic β-hairpin structure (12 is a truncated
9-mer).
In this study, we were primarily interested in demonstrating
an effect of peptide photoswitching on intracellular uptake.
Hence, we quantified relative fluorescence intensities on the
images obtained at 5 μM peptide concentration using ImageJ.
The results are summarized in Figure 5. Peptide 4 showed the
largest uptake difference, followed by 1 and 5.
A closer look at the images revealed large fluorescent
patches, which cannot be assigned to any cellular structure. We
attribute these patches to extracellular peptide aggregates that
could not be completely quenched with TB (see Figure 6).
Comparing the cellular uptake results with the HPLC RTs
and the data of the MTT assays, no clear correlations between
hydrophobicity, toxicity and uptake assessed by the
fluorescence intensity were found for the whole peptide set 1–
8. However, some trends could be identified within the two
peptide series, 1–5 and 6–8. Oligoarginine peptides 6–8 did
not change hydrophobicity upon photoswitching, and below
10 μM did not reveal significant changes in cytotoxicity upon
switching; peptides 7–8, but not 6, were taken up to a similar
extent in both photoforms. The difference in uptake of the
Figure 3. Confocal microscopy images displaying concentration-dependent uptake in live HeLa cells. The scale bars are 50 μm. Cells (1.5×104 perwell) were
incubated for three hours at 37 °C with the peptides at the indicated concentration, washed three times before TB was added to quench the non-internalized
fluorescence. Stained nuclei and brightfield pictures are omitted for clarity. Open forms were prepared in situ with 590 nm light to ensure the concentrations
of the corresponding peptide photoforms were identical.
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smallest peptide 6, however, suggests that the changes in
backbone flexibility (upon photoswitching of the DAE moiety)
are not sufficient to affect the larger polycationic macrocycles.
Fortunately, our concept worked better for the less charged
amphiphilic peptides 1–5. Here, we observed that photo-
isomerization-driven changes in macrocycle backbone structure
and dynamics can influence the cell penetrability in the desired
way: the more flexible open forms were consistently more
active, as had been observed also with other bioactive DAE-
derived peptidomimetics.[36] Peptides 1–3 were designed to
benefit in the open form from backbone structuring by
aromatic π-π-interactions between Phe/Nal, Trp/Phe and Phe/
Phe residues, whereas peptide 5 was a control. Judging from
ΔRTs (Table 2), the control peptide indeed exhibits less
structuring upon photoisomerization, and 1–3 could be ranked
as 1>3>2. The Trp analogue 2 did not demonstrate a big
change in hydrophobicity or uptake efficiency upon photo-
switching, hence the order remained. However, the control
peptide 5 appeared to show more photoswitchable uptake,
exceeding the differences between the two photoforms of
peptides 2 and 3. On the other hand, peptide 4 seems to
perform as expected – the high ΔRT values translated into
large uptake differences. The most hydrophobic naphthylala-
nine-containing analogue 1 had the largest difference in
retention time (i. e. was most structured in the open form) but
presumably was less effective in the cellular uptake assay as it
suffered from extracellular aggregation. Indeed, we noticed
differences in the images when performing the uptake experi-
ments with and without TB quenching for all amphipathic
peptides. Figure 6 illustrates the fluorescence difference for
peptide 4 in such case (compare to Figure 3). At first glance,
the photoswitching effect appears to be pronounced in
Figure 6, however, it is evident that a large fraction of the
fluorescence has to be assigned to extracellular peptide.
It appears that in more hydrophobic macrocycles the DAE-
photoisomerization affects not only the cell permeability, but
even more so the polarity-driven affinity of the peptides to the
membrane surface, as well as their ability to self-aggregate.
Accordingly, the open forms have a higher membrane binding
affinity, but they also aggregate more vigorously - presumably
due to their increased hydrophobicity. Any subsequent inter-
nalization does not occur (for the fraction remaining in the
large extracellular aggregates). It is also possible that aggre-
gated entities undergo different internalization pathways,
compared to monomeric species.[37]
In summary, we have synthesized 8 fluorescein-labelled
photoswitchable cyclic cell-penetrating peptides with varying
size and amino acid composition and 4 non-photoswitchable
controls. Two photoforms of these peptides showed different
retention times in reversed-phase HPLC, with the open form
isomers being consistently more hydrophobic. The peptides
did not show significant cytotoxicity at concentrations <10 μM.
Figure 4. Magnified view of the HeLa cells incubated with peptides 4 and 8
at 5 μM concentration to visualize the fluorophore cellular localization.
Nuclei were stained with Hoechst. The scale bars are 10 μm.
Figure 5. Fluorescence intensity of the open and closed photoforms of the
peptides 1–12 and the ratio between open and closed forms for the
photoswitchable peptides 1–8 penetrated into HeLa cells. Microscopy data
from the cells exposed to 5 μM peptide solutions for three hours at 37 °C in
the growth media after TB quenching was used. Ten to seventeen frames
from at least three different locations were averaged. Statistical analysis was
done with one-way ANOVA, relating to the closed/open ratio of peptide 1
and within he controlpeptide series.*P<0.05, **P<0.01, and ***P<0.005.
Figure 6. Fluorescence images of peptide 4 at 5 μM without extracellular
fluorescence quenching by Trypan Blue. The scale bars are 50 μm. Clusters
of bright green patches corresponding to extracellular fluorescence can be
observed.
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Except for two oligoarginine analogues, all peptides were well
taken up into HeLa cells at a concentration of 5 μM in their
open forms. All open forms showed at least to some extent a
higher uptake than the respective closed forms. Peptide 4
demonstrated 6.5 fold difference in intracellular fluorescence
intensity. Notably, we could demonstrate here that photo-
switching to the more cell-permeable compounds can be
achieved by red light in cyclic peptides that were modified
with a DAE fragment.
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